Substance Use Disorder (SUD) – Page 3

9Feb2023

Senior Associates at Bizzell Co-author NIDA Report on Improving Adolescent Health

According to numerous reports, it takes roughly 17 years ^[1] for research findings to find their way into routine clinical practice, depriving adults, and children of timely and effective therapeutic care. The improvement of adolescent health ultimately depends on access to timely research and scientific findings from the National Institute on Drug Abuse (NIDA) to better educate health care professionals, policymakers, adolescents, and their families. The “National Institute of Drug Abuse: Dissemination of Scientific Knowledge to Improve Adolescent Health” report spotlights NIDA’s vigorous efforts to accomplish the dissemination of evidence-based information achieved through varying approaches to diverse and targeted audiences; more specifically on substance use disorders (SUD) in the adolescent population.

The NIDA Clinical Trials Network Dissemination Initiative contract, held by Bizzell US, is overseen by co-authors Dr. Todd Mandell and Kenyatta Crenshaw. Within the report, the co-authors share evidence-based educational resources and materials developed to reduce the persistent gap between the publication of research findings on the treatment of SUDs and best practices for implementation and adoption in clinical practice. Dr. Mandell and Ms. Crenshaw also address the Mentor Facilitated Training Program (MFT), which is part of the NIDA Clinical Trials Network Dissemination Initiative contract. An overview of the MFT program is provided in the article, demonstrating how trainees in the field of substance use are encouraged to expand their depth of knowledge by the 1) identification of gaps in substance abuse training; and 2) dissemination of NIDA-sponsored, evidence-based resources/tools to their peers. The study was published in the Child and Adolescent Psychiatric Clinics of North American Volume 32, Issue 1, January 2023.

“I would like to congratulate Dr. Mandell and Ms. Crenshaw, and the other contributing authors, on the publication of the report, the recommendations are another imperative step to ensuring that the dissemination and access to critical data and tools is widely accessible to the public health community” said Anton C. Bizzell, MD, Chairman & CEO of Bizzell.

[1] Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med 2011;104(12): 510–20. Accessed December 14, 2021.

About Bizzell US

Established in 2010, Bizzell US is a U.S. Small Business Administration (SBA) HUBZone-certified strategy, consulting, and technology firm with a mission to improve lives and accelerate change. Bizzell US develops innovative solutions to some of the most critical issues of our time such as health care services equity, global health, workforce innovation, and other urgent needs facing the world. Under the leadership and vision of founder, Anton C. Bizzell, MD, the company has grown into a thriving firm, headquartered in New Carrollton, Maryland, with staff and offices in various regions around the country, including California, Colorado, Connecticut, Oklahoma, and Georgia, and globally in Africa, Asia, and Central America. Learn more about how we develop data-driven, research-informed, innovative solutions to complex, real-world challenges. Learn more at www.BizzellUS.com

2Aug2022

Bizzell Awarded Four SAMHSA IDIQ Domains

Bizzell US (Bizzell), a global strategy, consulting, and technology firm, is excited to continue its successful partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA). Bizzell has been awarded four domains as a prime contractor on SAMHSA’s Indefinite Delivery Indefinite Quantity (IDIQ) contract through 2027. The IDIQs help SAMHSA achieve its goal of reducing the impact of substance abuse and mental illness on America’s communities.

Through this award, Bizzell is eligible to compete for new contracts under the following domains:

Domain I: Feasibility, Pilot, and Evaluation Projects
Domain II: Statistical Projects
Domain V: Technical Assistance and Training Projects
Domain VI: Planning, Implementation, and Report Support Projects (8a and HUBZone)

Since Bizzell’s inception, the firm has worked with SAMHSA and other agencies within the Department of Health and Human Services to accelerate behavioral health advancements and improve services and resources for communities within the United States and across the globe. Bizzell has a full range of capabilities that can support SAMHSA’s mission, and includes program and project management, data analytics, evaluation and learning, and technical assistance and training.

Bizzell has conducted a wide range of feasibility studies, evaluation projects, and didactic learning seminars to strengthen health system interventions and training, foster data-informed decisions, and improve program outcomes and impact. Specifically, we’ve partnered with SAMHSA to provide direct technical assistance and support services to opioid treatment programs nationwide. Additionally, we’ve delivered in-person and web-based provider trainings in the areas of prevention treatment and recovery, substance use disorder and maternal and infant health, effective uses of medication assisted treatment, and improving cultural competence in substance abuse treatment.

“As a company, Bizzell is passionate about developing innovative solutions that lead to positive health outcomes,” says Anton Bizzell, M.D., President and CEO of Bizzell. “We are energized to support SAMSHA’s critical work to advance the nation’s behavioral health—especially now as more people struggle with mental health and substance use concerns and the demand for effective and accessible behavioral health services is growing.”

About Bizzell

Established in 2010, Bizzell US is U.S. Small Business Administration (SBA) HUBZone certified strategy, consulting, and technology firm with a mission to improve lives and accelerate change. Bizzell US develops innovative solutions to some of the most critical issues of our time such as health care services equity, global health, workforce innovation and other urgent needs facing the world. Under the leadership and vision of founder, Anton C. Bizzell, MD, the company has grown into a thriving firm headquartered in New Carrollton, Maryland with staff and offices in various regions around the country including California, Colorado, Oklahoma, and Georgia, and globally in Africa, Asia, and Central America. Learn more about how we develop data-driven, research-informed, innovative solutions to complex-real-world challenges. Learn more at BizzellUS.com.

The Bizzell Group Contact
Chad Brown DM, Chief Administrative Officer
301-459-0100 | cbrown@thebizzellgroup.com

27Jul2022

Utilizing Behavioral Therapy to Address Stimulant Use Disorder

Bizzell US, in partnership with The University of Vermont’s Center on Rural Addiction has produced an interactive educational video for clinicians and practitioners highlighting Contingency Management options for addressing stimulant use disorders.

With rural stimulant overdoses now higher than in urban counties (6.7 vs 4.8 per 100,000.) ^[1] Hedegaard H, Spencer MR. Urban–rural differences in drug overdose death rates, 1999–2019. NCHS Data Brief, no 403. Hyattsville, MD: National Center for Health Statistics. 2021. DOI: https://dx.doi.org/10.15620/cdc:102891, a renewed focus on combating addiction within these remote communities has taken on a new sense of urgency. “This video adds an important, well studied tool for addressing stimulant use disorder,” said Dr. Todd Mandell of Bizzell US who specializes in substance use and mental health and who was the lead producer of the educational video.

According to the Centers for Disease Control and Prevention (CDC), in 2018, 40% of all overdose deaths were attributed to stimulate use. Until recently there have not been medical treatment alternatives for practitioners treating patients with stimulant use disorder which makes the use of Contingency Management even more urgent.

The video highlights the history of the development of Contingency Management and stresses the key components of a successful program.

To view the educational video please visit: http://uvmcm.modernepic.net

[1] Hedegaard H, Spencer MR. Urban–rural differences in drug overdose death rates, 1999–2019. NCHS Data Brief, no 403. Hyattsville, MD: National Center for Health Statistics. 2021. DOI: https://dx.doi.org/10.15620/cdc:102891

21Oct2021

3 Xanax Addiction Signs to Lookout For

Nearly 52 million Americans 18 and older are living with a mental illness and/or substance use disorder. In the midst of the COVID-19 pandemic, reports of people suffering from panic disorders and anxiety are increasing. A common medication for treating panic disorders and anxiety is a prescription drug called Xanax. While Xanax can help relieve anxiety and panic symptoms, it is highly addictive. It is important that individuals taking Xanax become aware of the signs of an addiction to Xanax, which can include withdrawing from relationships and preoccupation with your Xanax use. As individuals become preoccupied with maintaining a steady supply of Xanax, financial troubles and concerning behaviors may increase. In a recent WebMD Connect to Care article on signs of Xanax addiction, Dr. Anton C. Bizzell, CEO of The Bizzell Group and a substance abuse expert, highlighted some additional telltale signs: “Maintaining a supply of the drug on hand, mixing with alcohol or other drugs, and developing dangerous behaviors to obtain the prescription, including stealing or getting it from the streets.”

Recognizing the signs of an addiction is an important step towards getting help to treat an addiction—for yourself or others you love.

Previous page 1 2 3 4 5 Next page

Tag Archives: Substance Use Disorder (SUD)